development collaboration Archives | Curadigm https://curadigm.elementi-design.com/tag/development-collaboration/ Together To Reshape Healthcare Thu, 15 Apr 2021 11:01:55 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.4 https://curadigm.elementi-design.com/wp-content/uploads/2019/12/cropped-curadigm-icon_512x512-32x32.png development collaboration Archives | Curadigm https://curadigm.elementi-design.com/tag/development-collaboration/ 32 32 CURADIGM ANNOUNCES COLLABORATION WITH SANOFI AS PART OF THE SANOFI ITECH AWARDS PROGRAM https://curadigm.elementi-design.com/curadigm-sanofi-itech-awards-collaboration/ Mon, 25 Jan 2021 22:00:49 +0000 https://www.curadigm.com/?p=1059 Curadigm, an early-stage nanotechnology company dedicated to improving treatment outcomes by shifting the therapeutic delivery paradigm, today announced the selection of its project for the Sanofi iTech Awards program with its proprietary Nanoprimer technology. The Sanofi iTech Awards program aims to identify external innovations with the potential to significantly improve drug discovery and design, drug delivery and drug development within Sanofi. […]

The post CURADIGM ANNOUNCES COLLABORATION WITH SANOFI AS PART OF THE SANOFI ITECH AWARDS PROGRAM appeared first on Curadigm.

]]>
  • Curadigm’s project involving its proprietary Nanoprimer technology has been selected as part of the Sanofi iTech Awards Program as a highly promising option to significantly improve gene therapy development
  • This selection is formalized through a one-year agreement with Sanofi, coming with 100k€ in funding and scientific exchanges
  • Nanoprimer technology is designed to improve bioavailability and reduce hepatic toxicity by temporarily occupying the clearance pathways in the liver, thereby allowing more of intravenously-administered therapeutics to reach target tissues
  • This selection for the Sanofi iTech Awards Program advances Curadigm’s strategic partnership strategy, and aligns with Sanofi’s efforts to improve the efficacy of gene therapy product candidates

This partnership as part of the iTech Awards Program is a tremendous opportunity to accelerate our mission of improving treatment outcomes for intravenously-administered therapeutics. We are proud that Sanofi has recognized the strategic opportunity to evaluate pairing our Nanoprimer technology with their gene therapy pipeline, potentially expanding the ability to offer the benefits of these product candidates to more patients. We look forward to pairing our scientific expertise with Sanofi’s considerable resources so that we can begin generating data in gene therapy and continue to evolve the therapeutic paradigm.

Matthieu Germain, CEO of Curadigm

Paris, France, Cambridge, Massachusetts (USA), 25 January 2021 – Curadigm (the “Company”), an early-stage nanotechnology company dedicated to improving treatment outcomes by shifting the therapeutic delivery paradigm, today announced the selection of its project involving proprietary Nanoprimer technology for the Sanofi iTech Awards program. The Sanofi iTech Awards program aims to identify external innovations with the potential to significantly improve drug discovery and design, drug delivery and drug development within Sanofi. Curadigm’s project selection for this program underscores the potential of Curadigm’s Nanoprimer to address barriers to the development of promising therapeutics, including nucleic acid-based product candidates.

Nanoprimer technology is designed to precisely and temporarily occupy the therapeutic clearance pathways in the liver. It is administered intravenously, immediately before administration of the therapy, and acts to prevent rapid clearance—thereby increasing bioavailability and subsequent accumulation of therapeutics in the targeted tissues. (Watch the video)

The selection to the Sanofi iTech Awards Program involves 100 k€ in funding for one year and scientific exchanges with Sanofi to establish proof of concept. The goal of the project will be to prove that Curadigm’s Nanoprimer can improve biodistribution and enhance the efficiency of gene therapy product candidates, potentially expanding and accelerating the ability of these product candidates to provide significant benefits to patients.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life.

www.sanofi.com

The post CURADIGM ANNOUNCES COLLABORATION WITH SANOFI AS PART OF THE SANOFI ITECH AWARDS PROGRAM appeared first on Curadigm.

]]> CURADIGM ANNOUNCES THE SELECTION OF ITS NANOPRIMER TECHNOLOGY BY THE NATIONAL CANCER INSTITUTE https://curadigm.elementi-design.com/curadigm-announces-selection-of-its-nanoprimer-technology-by-the-national-cancer-institute/ Thu, 03 Sep 2020 10:26:47 +0000 https://www.curadigm.com/?p=1087 The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way. Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance. This temporarily increases the therapeutic’s bioavailability and subsequent accumulation in target tissue. […]

The post CURADIGM ANNOUNCES THE SELECTION OF ITS NANOPRIMER TECHNOLOGY BY THE NATIONAL CANCER INSTITUTE appeared first on Curadigm.

]]>

The selection of our nanoprimer by the NCL is a major step for Curadigm. The standardized cascade assay developed by the NCL is a great opportunity to accelerate the development of the Nanoprimer by providing additional data about its physico-chemical properties, safety and mechanism of action that will facilitate regulatory review. The results generated through this collaboration will also be instrumental in supporting our discussions with partners to develop their therapeutics with the Nanoprimer.

Matthieu Germain, CEO of Curadigm

Paris, France, 9 March 2020 – Curadigm (the “Company”), an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy, announced the selection of its Nanoprimer technology by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization, based on its potential to significantly impact treatments in multiple disease indications, including cancer.

The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way. Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance. This temporarily increases the therapeutic’s bioavailability and subsequent accumulation in target tissue. This mechanism, targeting the universal upstream pathways involved in intravenous drug clearance, means the Nanoprimer can be used in combination with multiple classes of nanomedicines including nucleic acid and small molecule therapeutics or gene editing technologies. (Learn more here)

Through this collaboration, the NCL, a leader in the characterization and development of Nanomedicines, will perform in-depth pre-clinical characterizations. These studies will support the Nanoprimer’s development, driving advancement toward filing an Investigational New Drug (IND) with the Food and Drug Administration (FDA) and future clinical development. This work will also support ongoing and future collaborations combining the Nanoprimer with therapeutics across diverse clinical indications.

Curadigm is a 2019 Nanobiotix spin-off, that aims to reshape and elevate the efficacy of intravenously administered therapeutics. The Nanoprimer technology is based on engineered, biocompatible nanoparticles that are administered just prior to the therapeutic and acts rapidly to temporarily occupy the Kupffer and liver sinusoidal endothelial (LSEC) cells. This precision- based approach leads to enhanced systemic bioavailability for increased therapeutic action.

About NCL

The NCL was established to study the use of nanoparticles and nanomedicines to advance cancer research and to accelerate the development of promising and safe nanotechnology-based cancer therapeutics. The program provides pre-clinical testing and services on a competitive acceptance basis to companies, such as Curadigm, and is working in concert with other US agencies such as the FDA to accelerate the use of nanomedicines from early-stage development to clinical applications.

ncl.cancer.gov

The post CURADIGM ANNOUNCES THE SELECTION OF ITS NANOPRIMER TECHNOLOGY BY THE NATIONAL CANCER INSTITUTE appeared first on Curadigm.

]]>